Literature DB >> 2757750

Nucleoside analogues: 8. Some isomers of B.3839, the original 5-fluorouracil/nitrosourea molecular combination, and their effect on colon, breast and lung tumours in mice.

R S McElhinney1, J E McCormick, M C Bibby, J A Double, G Atassi, P Dumont, G Pratesi, M Radacic.   

Abstract

This study describes the manipulation of secondary products arising from the synthesis of the prototypical molecular combination of 5-fluorouracil (5-FU) and chloroethylnitrosourea (CNU), B.3839, in order to investigate the effects produced by connecting the C-S-C-C-CNU chain to the 5-FU ring in different ways. The isolation of phthalimide precursors of these compounds and the transformation into CNUs is described. Anti-tumour activity of these molecular combinations against a series of experimental murine colon, lung and mammary tumours is presented. The spectrum of anti-tumour activity displayed is interesting but defies simple explanation without further detailed in vivo pharmacokinetic and metabolism studies in order to define optimal profiles for activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2757750

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  3 in total

1.  Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model.

Authors:  P M Loadman; M C Bibby; J A Double; R S McElhinney
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

2.  Influence of O6-benzylguanine on the anti-tumour activity and normal tissue toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea and molecular combinations of 5-fluorouracil and 2-chloroethyl-1-nitrosourea in mice.

Authors:  M C Bibby; M J Thompson; J A Rafferty; G P Margison; R S McElhinney
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

3.  Pre-clinical evaluation of a novel chloroethylating agent, Clomesone.

Authors:  A M Matthew; R M Phillips; P M Loadman; M C Bibby
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.